Answers are grounded in this paper and cite their sources.
High rates of local control are achieved with this SBRT regimen in medically inoperable patients with stage I NSCLC. Both local recurrence and toxicity occur late after this treatment. This regimen should not be used for patients with tumors near the central airways due to excessive toxicity.
No takes yet. Share an insight, caveat, or question.
Timmerman et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: